Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

23.23 +1.10 (+4.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
News headline image
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts ↗
 
Via Benzinga
News headline image
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
News headline image
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate ↗
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside 
Via InvestorPlace
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Analysts Have This To Say About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Sarepta Therapeutics Stock ↗
 
Via Benzinga
News headline image
Why Sarepta Therapeutics Stock Is Rising Today ↗
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400. 
Via Benzinga
Topics Stocks
News headline image
Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months ↗
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge. 
Via Benzinga
News headline image
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now ↗
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
News headline image
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir ↗
Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs... 
Via Benzinga
News headline image
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again ↗
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
News headline image
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday ↗
 
Via Benzinga
News headline image
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript ↗
SRPT earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
1 Top Growth Stock to Buy and Hold for 10 Years ↗
This company's lineup might look very different in a decade, but the end result will be the same for investors. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Stock Shows Improved Technical Strength ↗
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
News headline image
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst ↗
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. 
Via Investor's Business Daily
News headline image
2 Biotech Stocks to Buy Hand Over Fist in April ↗
These drugmakers have made important moves over the past year. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback ↗
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy. 
Via Investor's Business Daily
News headline image
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗
The threat is still emerging, but it could be significant. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.